BACKGROUND: Hepatitis C virus (HCV) is the major posttransfusion infection in multitransfused individuals in India with thalassemia major. To our knowledge, this study is the first conducted to correlate and comprehend the effects of the host interleukin (IL)28B gene polymorphism at loci rs12979860 and rs8099917 in spontaneous or interferon (IFN)-induced treatment response in the HCV-seroreactive individuals with thalassemia major.
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STUDY DESIGN AND METHODS: A total of 557
HCV-seroreactive individuals with thalassemia were processed for HCV viral genotyping and host IL28B single-nucleotide polymorphism analysis at loci rs12979860 and rs8099917.
RESULTS:
Of 557 individuals, 70.92% were found to be HCV RNA positive with Genotype 3 (95.18%) as predominant strain. A favorable CC allele at locus rs2979860 and TT allele at rs8099917 were 75.31 and 77.16%, respectively, which was strongly associated with spontaneous clearance of infection (p < 0.05). Of 85 IFNtreated cases, 56 achieved sustained virologic response (SVR) whereas 27 were relapsed cases. Among these patients who achieved SVR, a favorable CC/TT allele at rs12979860/rs8099917 was found to be predominant with 76.79 and 66.07%, respectively, whereas in the case of relapsed patients, unfavorable CT (55.56%) and TG (59.26%) alleles were found to be predominant. Additionally, low serum ferritin level was significantly associated with SVR.
CONCLUSION: CC at rs12979860 and TT at rs8099917 was strongly associated with spontaneous clearance and SVR in the population with thalassemia. Low age group and low serum ferritin level are important cofactors. This allelic pattern will aid clinicians in making an informed decision about prognosis and therapeutic management. H epatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease, affecting approximately 180 million people worldwide. 1 Studies suggest that 55%
to 85% of HCV-infected individuals develop chronic HCV infection, with a high probability of advancing to cirrhosis (20%-30%) and hepatocellular carcinoma (4%) over time. 2 Its transmission occurs from contaminated blood or blood products, infected syringes, or organ transplant. 1, 3, 4 In
India, approximately 12.5 million people are infected with HCV. 5 Its seroprevalence within the general population varies approximately 1% to 3% worldwide but it can increase up to 85%, depending on high-risk population groups like thalassemia, hemodialysis, and hemophilia or in intravenous drug users. Thalassemia is an inherited hematologic disorder where hemoglobin (Hb) production is halted or stopped due to abnormal synthesis of respective alpha (a) or beta (b) chains of Hb. Individuals with this disorder undergo lifelong blood transfusion to keep standard Hb levels of their health management. Additionally, the chances of being infected with transfusion-transmitted infections such as human immunodeficiency virus, HCV, and hepatitis B virus, which ultimately curtail their life span, are also very high. HCV is the leading liver disease, which increases the morbidity and mortality of those individuals. 7 India contributes to 10% of the annual world incidence of thalassemia with approximately 9,000 to 10,000 new cases each year. 8, 9 The seroprevalence of HCV infection in patients with thalassemia varies from 11% to 30% in India. [10] [11] [12] Patients with thalassemia who undergo multiple transfusions throughout their lifetimes are the major reservoir of HCV and a great challenge for its clinical management due to its window period. HCV is a small hepatotropic single-stranded enveloped RNA virus. Seven major genotypes and more than 67 subtypes have been identified worldwide based on HCV genome sequence diversity. 13 The distribution pattern of HCV genotypes in patients with chronic hepatitis shows that Genotype 3 is the predominant circulating strain in India followed by Genotype 1. 14 Gold standard therapy applied to HCV patients consists of a combination of pegylated interferon (Peg-IFN) a2a or b and ribavirin (RBV) for 24 to 48 weeks depending on HCV genotype and viremia as well as host factors such as age, sex, race, and liver fibrosis status. 2 Treatment options are limited for HCV-infected patients with thalassemia as Peg-IFN and RBV treatment also causes hemolysis and increases the transfusion requirements and iron toxicities in the individuals. 15 Currently, direct-acting antivirals (DAAs), in combination with Peg-IFN and RBV are about to become standard-of-care treatment that targets specific steps within the HCV life cycle. DAAs, which act as polymerase inhibitors, have the potential of higher cure rates and reduced treatment duration in combination with IFN and RBV. To date, there are no published data on activity of DAA therapy in HCV-infected patients, especially on the population with thalassemia from India. High ferritin load is another alarming risk factor for patients with thalassemia. A transfusion-dependent patient develops progressive accumulation of iron in organs such as liver, heart, and kidney, which is responsible for tissue damage and eventually death. 16 Pathologic accumulation of this metal within tissues aggravates the generation of reactive oxygen species that are mainly related to oxidative stress. The oxidation products arising from these macromolecules can initiate tissue injury either directly or indirectly. 17 Iron overload and HCV infection are independent risk factors for liver fibrosis progression, and their concomitant presence results in a progressive increase in risk. [23] [24] [25] Carriers of the homozygous variant of the good responder allele had a higher chance of achieving SVR. In contrast, the SVR rates in carriers with heterozygous genotype, rs12979860CT, were only slightly better, compared to the nonresponder genotype TT. 26 As the efficacy of current DAA methods are still not established in India, the clinicians still prefer to rely on IFN and RBV, which remains the method of choice of treatment. In this scenario, the prediction of response by determining the host response remains an important pretreatment factor of HCV-infected patients with thalassemia. Therefore, in this study, we have taken the first attempt to correlate and understand the effects of the host gene polymorphism at locus rs12979860 and rs8099917 in spontaneous or IFN-induced viremia clearance in the HCV-seroreactive multitransfused individuals of Eastern India with thalassemia major. The objectives of this study were to 1) deduce host IL28B SNP pattern at locus rs12979860 and rs8099917 in HCV-seroreactive individuals with thalassemia with spontaneous clearance, 2) perform a viral load-and genotype-based comparison of the effects of host IL28B polymorphisms in the progression of HCV infection at rs12979860 and rs8099917 alleles, and 3) correlate the effects of the host genetic patterns of IL28B loci with IFN treatment response and also its correlation with serum ferritin level.
MATERIALS AND METHODS

Ethical statement
Written as well as informed consent was obtained before the inclusion of the individuals in this study. The study is in accordance with the Helsinki Declaration of 1975 and was approved by the Institutional Ethical Committee, National Institute of Cholera and Enteric Diseases (Indian Council of Medical Research), Kolkata.
Design of the study and laboratory methods
A total of 3277 individuals with thalassemia major were enrolled in this study from January 2013 to December 2015, from our collaborating thalassemia clinics in Eastern India. Healthy controls consisted (n 5 150) of unrelated healthy subjects, and thalassemia controls (n 5 150), who were negative for viral hepatitis markers (Fig. 1 ). All patients with thalassemia major had undergone regular blood transfusions since detection of thalassemia to maintain the standard Hb level. Blood samples were collected by venipuncture, followed by demographic data collection with an elaborate questionnaire at the time of counseling. Both plasma and whole blood were collected and stored at 2808C until further analysis.
Definition of IFN treatment response
Rapid virologic response (RVR) was defined as an undetectable serum HCV RNA level (<50 IU/mL) after 4 weeks of treatment; SVR was defined as undetectable HCV RNA (<50 IU/mL) 24 weeks (6 months) after the end of treatment. Relapse was defined as undetectable HCV RNA at the end of therapy, but the reappearance of HCV RNA has been found; null response was defined as less than a 2-log-unit decrease in HCV RNA (IU/m#) from baseline after 12 weeks of therapy. 27 
Determination of clinical variables
Liver function variables like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined by kinetic rate methods, and total bilirubin by diazo method (Synchron CX5Pro, Beckman Coulter). Creatinine was determined by kinetic rate methods (Synchron CX5Pro, Beckman Coulter). Hemoglobin (Hb) and serum ferritin levels were estimated by an automated cell counter (Medonic CA530-16 Open, Merck) and chemiluminescence enzyme immunoassay methods (Access 2, Beckman Coulter), respectively.
Host (IL28B) genotype analysis
Genomic DNA was isolated from whole blood using a DNA blood mini kit (QIAamp, Qiagen) according to the manufacturer's instruction, and genomic DNA concentration was measured by a nanodrop spectrophotometer (Eppendorf). Host SNP genotyping at rs12979860 C/T was performed by means of a TaqMan allelic discrimination assay. The primers and probes were used as described by Ezzikouri and colleagues. 28 The probes were labeled with the fluorescent dye VIC and FAM, respectively. The genotype for each sample was determined by the software for allelic discrimination (SDS1.1, ABI 7500, Applied Biosystems). The SNPs at rs8099917 T/G were genotyped using a predesigned TaqMan SNP genotyping assay (Assay ID C_11710096_10, Applied Biosystems). All tests on samples were repeated twice to check the results for quality control. 
Virologic testing
Viral RNA was extracted from HCV-seroreactive serum samples. Briefly, 140 mL of serum was used to isolate total viral RNA using a viral RNA mini kit (QIAamp, Qiagen) according to the manufacturer's protocol and eluted with 50 mL of elution buffer. RNA was stored at 2808C until further use. Detection of HCV viral RNA was done by nested reverse transcription-polymerase chain reaction (RT-PCR) based on 5 0 noncoding region of HCV genome described elsewhere. 29 Briefly, first-round one-tube RT-PCR was performed in 20 mL total reaction volume containing 2 mL of isolated RNA and second-round nested PCR was performed in 25 mL total volume. A positive band at 256 bp in 1.5% agarose gel stained with ethidium bromide was observed in a gel documentation system (Bio-Rad). Quantitative HCV RNA was estimated using in-house Qiagen real-time quantitative RT-PCR kit (pathogen RT-PCR 1 IC kit, QuantiFast). The HCV primer and probe sequences were directed against the 5 0 noncoding region of the HCV genome. 30 The Fourth WHO International Standard for HCV, NIBSC Code 06/102, was used as standard. For HCV genotyping, nested RT-PCR-amplified amplicons of partial HCV core genome (405 bp) was gel purified and directly used for DNA sequencing analysis in an automated DNA sequencer (ABI 3130XL, Applied Biosystems) using a cycle sequencing kit (Big Dye terminator 3.1, Applied Biosystems). The genotypes of the sequences obtained were determined using the NCBI genotyping tool.
Statistical analysis
Continuous variables are presented as mean 6 standard deviation (SD) or median (range), while categorical variables are expressed as frequencies (%). The existence of differences in groups was assessed by means of chi-square test for linear trend when appropriate and calculating the odds ratio (OR) within 95% confidence interval (CI). A p value of not more than 0.05 was used as the criterion for significance. All the statistical analyses were performed computer software (SPSS, Version 16.0, SPSS, Inc.).
RESULTS
Demographic nature of the individuals
Of 3277 total study population, 557 patients with thalassemia were HCV seroreactive (Fig. 1) , of whom 56.19% (n 5 313) were males and the rest were females (n 5 244, 43.81%). Their ages ranged from 1.9 to 37 years with the mean 6 SD being 10.30 6 5.43 years. Their body weight ranged from 7.0 to 54.2 kg and height ranged from 64 to 172 cm (Table 1, Fig. 1 ). All the patients were diagnosed with thalassemia major within 6 months to 2 years of age. Most of the individuals undergo transfusions of 1 to 3 units of blood per month depending on their need. 
Clinical variables
The Hb level of the individuals ranged from 3.7 to 10.8 g/dL. The liver enzyme levels were found to be higher than the normal range (normal range of ALT, 7-56 IU/L; normal range of AST, 5-40 IU/L) in most of the individuals ranging from 21 to 368 IU/L for ALT and 18 to 490 IU/L in case of AST. The mean 6 SD ferritin level was found to be 2303.8 6 1573.1 ng/mL, ranging from as high as 9268.1 ng/mL to as low as 380 ng/mL (when the normal level ranges from 12 to 150 and 300 ng/mL for females and males, respectively). Bilirubin ranged from 0.7 to 7.9 mg/ dL, with a mean value of 1.94 6 1.07 mg/dL (when the normal level ranges from 0.3 to 1.2 mg/dL). The mean 6 SD creatinine level of the patients was 0.68 6 0.12 mg/dL (normal range is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women; Table 1 ).
Detection of HCV RNA and HCV genotype
Of 557 total HCV-seroreactive samples, 395 (70.92%) individuals were HCV RNA positive by nested RT-PCR and quantitative real-time PCR-based detection. Of 395 HCV RNA-positive individuals, 31.77% of individuals were found to have low viral load (within 5000 IU/mL), whereas 29.08% were below detection level (<50 IU/mL). A total of 228 HCV RNA-positive samples were successfully amplified for core-based genotyping. HCV core gene-based genotyping showed two major genotypes with only four subtypes circulated within our study population. HCV Genotype 3 (n 5 217, 95.18%) was the major prevalent strain followed by Genotype 1 (n 5 11, 4.82%) and the subtype characterization showed: 1a (n 5 4, 1.75%), 1b (n 5 7, 3.07%), 3a (n 5 192, 84.21%), and 3b (n 5 25, 10.97%; Table  1 ).
Distribution of host IL28B polymorphisms
IL28B host SNPs at locus rs12979860 and rs8099917 were determined on 557 HCV-seroreactive individuals with thalassemia. A favorable CC allele at locus rs12979860 was found in 53.14% (296 of 557), whereas unfavorable CT and TT alleles were found in 40.57% (226 of 557) and 6.29% (35 of 557) individuals, respectively. At locus rs8099917, the favorable TT allele was found in 69.84% (n 5 389)
followed by TG and GG found in 23.70 and 6.46% of individuals, respectively ( Table 1) . The control population consisted of two groups: individuals with thalassemia without HCV (n 5 150, age-sex-matched controls), in whom the frequencies of CC, CT, and TT genotypes at locus rs12979860 were 54, 39.33, and 6.67%, respectively, and healthy controls. Analysis of the allele frequencies shows a C allele frequency of 0.75, while the T allele frequency was 0.25. The distribution of allelic frequencies was in accordance to the Hardy-Weinberg equilibrium (v 2 5 0.05, p < 0.05). At locus rs8099917, the TT, TG, and GG frequencies were 68.33, 23.34, and 7.33%, respectively. The frequencies of T and G alleles were found to be 0.8 and 0.2, respectively (v 2 5 8.55, p < 0.05), at rs8099917 by Hardy-Weinberg equilibrium, whereas in the case of healthy individuals (n 5 150, sampled randomly within the population to determine the allele frequency), the frequencies of CC, CT, and TT genotypes at locus rs12979860 were 73.33, 22, and 4.67%, respectively, and the frequencies of TT, TG, and GG genotypes at rs8099917 were 70.67, 28.67, and 0.66%, respectively (Table 1) . HCV genotypewise IL28B host SNP distributions at rs12979860 and rs8099917 are summarized in Table 2 . HCV Genotype 3 was the major circulating strain followed by Genotype 1, and no significant correlation was found between the host genotype and the HCV genotype (Table 2) . No significant correlations were found between the host genotype (at loci rs12979860 and rs8099917) and mean viral load ( Table  2 ). The percentage of CC allele at rs12979860 was much higher (75.31%) than the unfavorable CT/TT allele (24.69%), whereas at rs8099917, the favorable TT allele was more dominant (77.16%) than TG (22.84%) in 162 individuals who spontaneously cleared the infection (Table 3) .
IL28B polymorphisms and response to IFN therapy
A total of 147 patients were started Peg-IFN and RBV therapy, of whom 56 individuals abandoned the treatment regimen due to therapy-related side effects or poor economic background and six discontinued the follow-up procedure (Fig. 1) . A total of 85 individuals (3a, 80.01%, n 5 68; 3b, 15.29%, n 5 13; 1a, 2.35%, n 5 2; 1b, 2.35%, n 5 2) completed the therapy. Of the 85 individuals, 56 (65.88%; 3a, 55.29%; 3b, 8.24%; 1a, 1.18%; 1b, 1.18%) individuals achieved rapid virologic response followed by SVR.
Of those who achieved SVR, 76.79% of them carried a favorable IL28B CC genotype at locus rs12979860 and 66.07% had a favorable TT genotype at locus rs8099917. In individuals with relapsed IFN therapy, unfavorable CT and TT alleles at locus rs12979860 were 55.55 and 7.41%, while at rs8099917, unfavorable TG and GG genotypes were 59.26 and 7.41%, respectively. Null responder individuals (n 5 2) had unfavorable TT and TG genotypes at both rs12979860 and rs8099917 loci (Fig. 2 ).
DISCUSSION
The relationship between genetic polymorphisms in the vicinity of the IL28B gene and the response to Peg-IFN and RBV combined therapy for hepatitis C has been clearly demonstrated since the rs12979860 SNP was identified. 31 However, information on the possible influence of these polymorphisms on the course of hepatitis C infection in individuals with thalassemia major is very limited and incomplete at present. 7 In our earlier study, we found 18.7% HCV-seroreactive cases in the population in this region with thalassemia major. 32 Earlier studies have shown correlation of IL28B SNPs with IFN therapy in HCV chronic patients infected with Genotype 1 in Western countries 23, 24 and Genotype 3 in India. 33 However, none of the previous studies have typically focused on any particular HCV-infected high-risk population group. Studies conducted by different groups 7, 34, 35 explored the role of IL28B SNPs in thalassemia but their sample size was small and showed no correlation between HCV infection and serum ferritin load. To the best of our knowledge this is the first comprehensive study to find the role of IL28B at loci rs12979860 and rs8099917 in patients with thalassemia with or without HCV standard therapy in India. The Indian population is ethnically heterogeneous; therefore genetic variability is expected in different groups of the population. In our study population, frequencies of the favorable CC and TT genotypes at rs12979860 and rs8099917 were 53.14 and 69.84%, respectively, which is much less than that found in the study conducted by Firdaus and coworkers 33 in chronic HCV Genotype 3 patients in the same region. It was seen in our study that the percentage of CC allele at rs12979860 was much higher (73%) in healthy individuals without thalassemia whereas our control individuals with thalassemia were found to have a low proportion of the same allele (53%) than normal controls. Thus, it can be concluded that the percentage of the favorable CC allele at locus rs12979860 is less in the population with thalassemia compared to the normal population.
The average viral load of the individuals with C allele was found to be lower than that in the individuals with the T allele in case of rs12979860 locus, whereas for rs8099917, individuals with the T allele had lower viral load than individuals with the G allele. However, no significant correlation was found between the allele type and viral load (Table 2) . Also, the number of individuals having viral load below detection level was found to be much higher for the favorable alleles (C for rs12979860 and T for rs8099917; Table 2 ). The CC and TT alleles at rs12979860 and rs8099917, respectively, were found to have a strong association with spontaneous clearance; our results have reported that 75.31% individuals at rs12979860 with the CC allele and 77.16% with the favorable TT allele at rs8099917 had spontaneously cleared the infection. Thus, our results corroborate the fact that favorable alleles at both rs12979860 and rs8099917 loci and low age group are two significant factors that strongly contribute to the spontaneous clearance of the virus from the host system than without spontaneous clearance individuals (p < 0.05; Table 3 ). Our data are also in accordance with the reports published elsewhere, which show that carriers of the favorable genotypes at rs12979860 and rs8099917 have a higher rate of spontaneous clearance of HCV during the acute phase of the infection. 34, 36 Because the serum ferritin level is found to be high in patients with thalassemia, IFN treatment in HCV-infected cases causes hemolysis and increases the transfusion requirements and iron toxicities. 15, 17 In our study population, 38.10% (n 5 56) abandoned the treatment due to side effects. The low age of this group adds to this factor. Additionally, the elevated level of hepatic iron load interferes with IFN treatment by resisting its activities and development of liver fibrosis in those individuals. 37 Elevation of iron may promote liver tissue injury by forming reactive oxygen species and inflammation in chronic hepatitis C infection, which decreases response to IFN therapy. 37, 38 Recently, the role of iron release from affected hepatocytes has been pointed out as an important element affecting the natural history of chronic hepatitis. 38 In fact, the serum iron load is increased in chronic hepatitis patients. 38 Serum ferritin is one of the independent factors of relapsed cases, especially in patients with thalassemia. We have found a significant correlation of low serum ferritin level with individuals who achieved SVR than in relapsing individuals (p < 0.05; Table 4 ). Results obtained from the 85 IFN-treated patients showed that the C and T alleles at rs12979860 and rs8099917 were important factors that determine the progression of HCV infection in individuals.
The CC allele at rs12979860 was found in the majority of individuals (76.7%) who had reached SVR. An unfavorable CT allele was found in 55.56% of individuals who had relapsed infection, and in individuals who were null responders to therapy 100% had an unfavorable TT allele. At the rs8099917 locus as well, results show that the TG allele was found in all individuals (100%) who had a null response to therapy (Fig. 2) . Thus, it could be said that the influence of favorable alleles at both regions with SVR and unfavorable alleles in case of relapsed individuals are significantly correlated (p < 0.05) in HCV-infected individuals with thalassemia (Table 5 ). In our study most IFN-treated individuals were infected with the Genotype 3 strain, and hence no correlation could be drawn between IL28B host and viral HCV genotype.
In conclusion, our study shows that favorable host genotypes of IL28B are strongly associated with spontaneous clearance of HCV and responsiveness to IFN therapy. Host genotyping demonstrated a great potential to be an important pretreatment factor and this could improve patient care in thalassemia major individuals. DAAs are arriving in India, but they are applied to HCV-infected patients; no such data are reported about the action of DAAs on thalassemia to date. The strength of this study was that it was the first such study performed on thalassemia individuals with in-depth focus on the IL28B responsiveness. The results generated could go a long way in aiding clinicians to take an informed decision about which treatment regimen and treatment duration to undertake for these patients. Therefore, in this scenario, we suggest that the IL28B polymorphism can influence the spontaneous clearance of HCV and the response to IFN, especially in patients with thalassemia through various mechanisms that regulate the replication of the virus and the immunologic response of the host. Iron overload in patients with thalassemia may have altered the host response to viral replication. This hypothesis and its action of mechanism need to be confirmed by other studies with large cohorts of patients from different geographical regions to draw a final conclusion. Although IFN-free oral therapy is becoming available in developing countries, the influence of IL28B SNPs might remain clinically relevant in economically backward setting population like those with thalassemia in a country like India.
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